Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$237598.0.

  • China Pharma Holdings' Free Cash Flow fell 52969.89% to -$237598.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $122692.0, marking a year-over-year increase of 11698.24%. This contributed to the annual value of -$538411.0 for FY2024, which is 2429.57% up from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Free Cash Flow is -$237598.0, which was down 52969.89% from $293323.0 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Free Cash Flow peaked at $939831.0 during Q3 2023, and registered a low of -$1.4 million during Q1 2023.
  • Over the past 5 years, China Pharma Holdings' median Free Cash Flow value was -$118324.0 (recorded in 2025), while the average stood at -$145710.9.
  • In the last 5 years, China Pharma Holdings' Free Cash Flow skyrocketed by 291159.24% in 2023 and then plummeted by 52969.89% in 2025.
  • Over the past 5 years, China Pharma Holdings' Free Cash Flow (Quarter) stood at -$205168.0 in 2021, then surged by 398.22% to $611862.0 in 2022, then tumbled by 104.39% to -$26850.0 in 2023, then skyrocketed by 790.1% to $185291.0 in 2024, then crashed by 228.23% to -$237598.0 in 2025.
  • Its last three reported values are -$237598.0 in Q3 2025, $293323.0 for Q2 2025, and -$118324.0 during Q1 2025.